Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain

Revista Brasileira de Psiquiatria

Volumn 35, Issue 4, 2013, Pages 380-386

  Valvassori, Samira S ^a   Bavaresco, Daniela V ^a   Scaini, Giselli ^a   Varela, Roger B ^a   Streck, Emilio L ^a   Chagas, Marcos H ^b   Hallak, Jaime E C ^b   Zuardi, Antonio W ^b   Crippa, José A ^b   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cannabidiol; Creatine kinase; Mitochondrial respiratory chain

Indexed keywords

CANNABIDIOL; CREATINE KINASE; CYTOCHROME C OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; HIPPOCAMPUS; MALE; NONHUMAN; PREFRONTAL CORTEX; RAT; SINGLE DRUG DOSE; SPECTROPHOTOMETRY;

ANIMALS; BRAIN; CANNABIDIOL; CREATINE KINASE; MALE; MITOCHONDRIA; RATS; RATS, WISTAR;

EID: 84891549251     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2012-0886     Document Type: Article

References (52)

1. Carlini EA, Santos M, Claussen U, Bieniek D, Korte F. Structure activity relationship of four tetrahydrocannabinols and the pharmacological activity of five semi-purified extracts of Cannabis sativa. Psychopharmacologia. 1970; 18: 82-93.
2. Grlic L. A comparative study on some chemical and biological characteristics of various samples of cannabis resin. Bull Narc. 1962; 14: 37-46.
3. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl). 1982; 76: 245-50.
4. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008; 30: 271-80.
5. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980; 21: 175-85.
6. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006; 39: 421-9.
7. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol--recent advances. Chem Biodivers. 2007; 4: 1678-92.
8. Bartova A, Birmingham MK. Effect of delta9-tetrahydrocannabinol on mitochondrial NADH-oxidase activity. J Biol Chem. 1976; 251: 5002-6.
9. Sarafian TA, Kouyoumjian S, Khoshaghideh F, Tashkin DP, Roth MD. Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. Am J Physiol Lung Cell Mol Physiol. 2003; 284: L298-306.
10. Athanasiou A, Clarke AB, Turner AE, Kumaran NM, Vakilpour S, Smith PA, et al. Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun. 2007; 364: 131-7.
11. Kato T, Takahashi S, Shioiri T, Inubushi T. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord. 1992; 26: 223-30.
12. Mancuso M, Orsucci D, LoGerfo A, Calsolaro V, Siciliano G. Clinical features and pathogenesis of Alzheimer's disease: involvement of mitochondria and mitochondrial DNA. Adv Exp Med Biol. 2010; 685: 34-44.
13. Orth M, Schapira AH. Mitochondria and degenerative disorders. Am J Med Genet. 2001; 106: 27-36.
14. Mattiasson G, Shamloo M, Gido G, Mathi K, Tomasevic G, Yi S, et al. Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat Med. 2003; 9: 1062-8.
15. Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR. Functions and effects of creatine in the central nervous system. Brain Res Bull. 2008; 76: 329-43.
16. Valvassori SS, Elias G, de Souza B, Petronilho F, Dal-Pizzol F, Kapczinski F, et al. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharmacol. 2011; 25: 274-80.
17. Jones G, Pertwee RG. A metabolic interaction in vivo between cannabidiol and 1-tetrahydrocannabinol. Br J Pharmacol. 1972; 45: 375-7.
18. Cassina A, Radi R. Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch Biochem Biophys. 1996; 328: 309-16.
19. Fischer JC, Ruitenbeek W, Berden JA, Trijbels JM, Veerkamp JH, Stadhouders AM, et al. Differential investigation of the capacity of succinate oxidation in human skeletal muscle. Clin Chim Acta. 1985; 153: 23-36.
20. Rustin P, Lebidois J, Chretien D, Bourgeron T, Piechaud JF, Rotig A, et al. Endomyocardial biopsies for early detection of mitochondrial disorders in hypertrophic cardiomyopathies. J Pediatr. 1994; 124: 224-8.
21. Hughes BP. A method for the estimation of serum creatine kinase and its use in comparing creatine kinase and aldolase activity in normal and pathological sera. Clinica Chimica Acta. 1962; 7: 597-603.
22. Pertwee RG. Pharmacological and therapeutic targets for D9 tetrahydrocannabinol and cannabidiol. Euphytica. 2004; 140: 73-82.
23. Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? J Neurosci Res. 2005; 79: 231-9.
24. Volz HR, Riehemann S, Maurer I, Smesny S, Sommer M, Rzanny R, et al. Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a (31)P chemical shift spectroscopic-imaging study. Biol Psychiatry. 2000; 47: 954-61.
25. Clark JB. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci. 1998; 20: 271-6.
26. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005; 10: 900-19.
27. Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, McGuire PK. Neural mechanisms for the cannabinoid modulation of cognition and affect in man: a critical review of neuroimaging studies. Curr Pharm Des. 2012; 18: 5045-54.
28. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis. 2005; 19: 96-107.
29. Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett. 2006; 399: 91-5.
30. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004; 89: 134-41.
31. Rizzuto R, De Stefani D, Raffaello A, Mammucari C. Mitochondria as sensors and regulators of calcium signalling. Nat Rev Mol Cell Biol. 2012; 13: 566-78.
32. Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B. Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci. 2009; 29: 2053-63.
33. Lenaz G, Genova ML. Structure and organization of mitochondrial respiratory complexes: a new understanding of an old subject. Antioxid Redox Signal. 2010; 12: 961-1008.
34. Grimm S. Respiratory chain complex II as general sensor for apoptosis. Biochim Biophys Acta. 2013; 1827: 565-72.
35. Fellman V. The GRACILE syndrome, a neonatal lethal metabolic disorder with iron overload. Blood Cells Mol Dis. 2002; 29: 444-50.
36. V Visapaa I, Fellman V, Vesa J, Dasvarma A, Hutton JL, Kumar V, et al. GRACILE syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation in BCS1L. Am J Hum Genet. 2002; 71: 863-76.
37. Sonnewald U, Hertz L, Schousboe A. Mitochondrial heterogeneity in the brain at the cellular level. J Cereb Blood Flow Metab. 1998; 18: 231-7.
38. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids. 2002; 66: 101-21.
39. Roser P, Vollenweider FX, Kawohl W. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry. 2010; 11: 208-19.
40. Costa B, Colleoni M. Changes in rat brain energetic metabolism after exposure to anandamide or delta(9)-tetrahydrocannabinol. Eur J Pharmacol. 2000; 395: 1-7.
41. Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 1991; 547: 267-74.
42. Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci. 2001; 21: 823-33.
43. Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci. 2004; 75: 633-8.
44. Bindukumar B, Mahajan SD, Reynolds JL, Hu Z, Sykes DE, Aalinkeel R, et al. Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008; 1191: 1-11.
45. Hemmer W, Wallimann T. Functional aspects of creatine kinase in brain. Dev Neurosci. 1993; 15: 249-60.
46. O'Gorman E, Beutner G, Wallimann T, Brdiczka D. Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. Biochim Biophys Acta. 1996; 1276: 161-70.
47. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999; 5: 347-50.
48. Tomimoto H, Yamamoto K, Homburger HA, Yanagihara T. Immunoelectron microscopic investigation of creatine kinase BBisoenzyme after cerebral ischemia in gerbils. Acta Neuropathol. 1993; 86: 447-55.
49. David S, Shoemaker M, Haley BE. Abnormal properties of creatine kinase in Alzheimer's disease brain: correlation of reduced enzyme activity and active site photolabeling with aberrant cytosol-membrane partitioning. Brain Res Mol Brain Res. 1998; 54: 276-87.
50. Streck EL, Amboni G, Scaini G, Di-Pietro PB, Rezin GT, Valvassori SS, et al. Brain creatine kinase activity in an animal model of mania. Life Sci. 2008; 82: 424-9.
51. Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, Battistelli M, et al. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med. 2006; 40: 837-49.
52. Watanabe A, Kato N, Kato T. Effects of creatine on mental fatigue and cerebral hemoglobin oxygenation. Neurosci Res. 2002; 42: 279-85.